The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis

Archives of Dermatological Research

Volumn 300, Issue 10, 2008, Pages 545-550

  Ohtsuka, Tsutomu ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporin; High sensitivity CRP; Psoriasis; Trough level

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; CYCLOSPORIN A; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LABORATORY TEST; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CYCLOSPORINE; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PSORIASIS;

EID: 55049133699     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-008-0887-5     Document Type: Article

References (38)

1. P Barrera AM Boerbooms LB van de Putte JW van der Meer 1996 Effects of antirheumatic agents on cytokines Semin Arthritis Rheum 25 234 253 10.1016/S0049-0172(96)80035-7
2. MH Beresini D Davalian S Alexander 1993 Evaluation of EMIT cyclosporine assay for use with whole blood Clin Chem 39 2235 2241
3. E Bonora 2006 The metabolic syndrome and cardiovascular disease Ann Med 38 64 80 10.1080/07853890500401234
4. FC de Beer CR Hind KM Fox 1982 Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction Br Heart J 47 239 243 10.1136/hrt.47.3.239
5. T Fredriksson U Pettersson 1978 Severe psoriasis-oral therapy with a new retinoid Dermatologica 157 238 244
6. JM Gelfand AL Neimann DB Shin 2006 Risk of myocardial infarction in patients with psoriasis JAMA 296 1735 1741 10.1001/jama.296.14.1735
7. P Gisondi MD Giglio C Cotena G Girolomoni 2008 Combining etenercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial Br J Dermatol 158 1345 1349 10.1111/j.1365-2133.2008.08564.x
8. P Gisondi G Tessari A Conti 2007 Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study Br J Dermatol 157 68 73 10.1111/j.1365-2133.2007.07986.x
9. CE Griffiths L Dubertret CN Ellis 2004 Cyclosporin in psoriasis clinical practice: an international consensus statement Br J Dermatol 150 Suppl 67 11 23 10.1111/j.0366-077X.2004.05949.x
10. CE Griffiths A Katsambas BA Dijkmans 2006 Update on the use of cyclosporin in immune-mediated dermatoses Br J Dermatol 155 Suppl 2 1 16 10.1111/j.1365-2133.2006.07343.x
11. T Henseler E Christopher 1995 Disease concomitance in psoriasis J Am Acad Dermatol 32 982 986 10.1016/0190-9622(95)91336-X
12. VM Heydendael PI Spuls IJ Ten Berge 2002 Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels Br J Dermatol 147 122 129 10.1046/j.1365-2133.2002.04836.x
13. G Krueger CN Ellis 2005 Psoriasis-recent advances in understanding its pathogenesis and treatment J Am Acad Dermatol 53 Suppl S94 S100 10.1016/j.jaad.2005.04.035
14. M Lebwohl C Ellis A Gottlieb 1998 Cyclosporine consensus conference: with emphasis on the treatment of psoriasis J Am Acad Dermatol 39 464 475 10.1016/S0190-9622(98)70325-1
15. P Libby 1995 Molecular bases of the acute coronary syndromes Circulation 91 2844 28450
16. G Liuzzo LM Biasucci JR Gallimore 1994 The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med 331 417 424 10.1056/NEJM199408183310701
17. JE Losa García F Mateos Rodríguez 1998 Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages Respir Med 92 722 728 10.1016/S0954-6111(98)90002-6
18. RJ Ludwig C Herzog A Rostock 2007 Psoriasis: a possible risk factor for development of coronary artery calcification Br J Dermatol 156 271 276 10.1111/j.1365-2133.2006.07562.x
19. M Malerba P Gisondi A Radaeli 2006 Plasma homocysteine and folate levels in patients with chronic plaque psoriasis Br J Dermatol 155 1165 1169 10.1111/j.1365-2133.2006.07503.x
20. L Mallbris O Akre F Granath 2004 Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients Eur J Epidemiol 19 225 230 10.1023/B:EJEP.0000020447.59150.f9
21. L Mallbris CT Ritchlin M Stahle 2006 Metabolic disorders in patients with psoriasis and psoriatic arthritis Curr Rheumatol Rep 8 355 363 10.1007/s11926-006-0065-8
22. A Maseri 1997 Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon N Engl J Med 335 1014 1016 10.1056/NEJM199704033361409
23. MR Meyers N Gokce 2007 Endothelial dysfunction in obesity: etiological role in atherosclerosis Curr Opin Endocrinol Diabetes Obes 14 365 369
24. M Mitamura N Nakano T Yonekawa 2007 T cells are involved in the development of arthritis induced by anti-type II collagen antibody Int Immunopharmacol 7 1360 1368 10.1016/j.intimp.2007.05.021
25. G Mockli PM Kabra TW Kurtz 1990 Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist J Am Acad Dermatol 23 1275 1279
26. AL Neimann DB Shin X Wang 2006 Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 829 835 10.1016/j.jaad.2006.08. 040
27. A Peserico G Zanetti S Padovan 1988 Relationship between body weight and blood pressure and some metabolic parameters in psoriatic patients Br J Dermatol 118 191 194 10.1111/j.1365-2133.1988.tb01773.x
28. PM Ridker 2001 High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 103 1813 1818
29. P Rocha-Pereira A Santos-Silva RI Rebelo 2004 The inflammatory response in mild and in severe psoriasis Br J Dermatol 150 917 928 10.1111/j.1365-2133. 2004.05984.x
30. B Schieffer E Schieffer D Hilfiker-Kleiner 2000 Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability Circulation 101 1372 1378
31. MP Schon WH Boehncke 2005 Psoriasis N Engl J Med 353 848 850 10.1056/NEJMc051541
32. D Seckin L Tokgozoglu S Akkaya 1994 Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 31 445 449
33. M Seishima M Seishima S Mori A Noma 1994 Serum lipid and apolipoprotein in patients with psoriasis Br J Dermatol 130 738 742 10.1111/j.1365-2133.1994. tb03411.x
34. N Shibata T Hayakawa N Hoshino 1998 Effect of obesity on cyclosporine trough concentrations in psoriasis patients Am J Health Syst Pharm 55 1598 1602
35. W Steimer 1999 Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 45 371 381
36. M Wakkee HB Thio EP Presn 2007 Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients Athrosclerosis 190 1 9 10.1016/j.atherosclerosis.2006.07.011
37. MM Ward 1999 Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus Arthritis Rheum 42 338 346 10.1002/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U
38. J Zhu AA Quyyumi JE Norman 2000 Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels Am J Cardiol 85 140 146 10.1016/S0002-9149(99)00653-0